Focal Segmental Glomerulosclerosis Market by Segment: Global Industry Trends, Size, Growth, Opportunity and Forecast 2022-2028

 

Segmental Focal Glomerulosclerosis (FSGS) is a rare kidney disease that affects the filtration system (glomeruli) of the kidneys, causing severe scarring and end-stage renal disease. According to an article published in the Clinical Journal of the American Society of Nephrology in 2017, the incidence of FSGS is 1.5 times higher in males than in women. Edema, proteinuria, weight gain, elevated cholesterol, and proteins in the blood are all indications of FSGS.

The expanding population, as well as the significant untapped market prospects due to a limited number of pipeline items, are helping to enhance it. Non-government organizations' continued efforts to raise awareness about rare diseases, as well as increased funding for rare disease research, are proving advantageous to the industry.

The Focal Segmental Glomerulosclerosis Market can be divided into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis according on the disease type. Primary focal segmental glomerulosclerosis had the largest market share of the two in 2016, accounting for 79.8% of the total market. Primary focal segmental glomerulosclerosis, also known as primary idiopathic/genetic focal Focal Segmental Glomerulosclerosis Market, is a type of focal segmental glomerulosclerosis disease with no known or visible cause. Growing awareness of the disease and how to manage it is at the forefront of the segment's growth.

The global Focal Segmental Glomerulosclerosis Market for focal segmental glomerulosclerosis (FSGS) can be divided into diagnostic and treatment, depending on how the condition is managed. The diagnosis section can be further subdivided into creatine tests, kidney biopsy, and so on. Drug therapy, kidney transplantation, and dialysis are the three types of treatment available. The treatment segment now accounts for the majority of revenue in the market for focal segmental glomerulosclerosis (FSGS). This is due to the market's large unmet requirements. In the coming years, the segment will benefit from a promising pipeline of new compounds and their approval.

Key players

GlaxoSmithKline plc., Novartis AG, Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca plc., Sanofi S.A., and Teva Pharmaceutical Industries Ltd. are among the major competitors in the focal segmental glomerulosclerosis (FSGS) industry.